CA3016588A1 - Methods and compositions for treatment of zika virus infection - Google Patents

Methods and compositions for treatment of zika virus infection Download PDF

Info

Publication number
CA3016588A1
CA3016588A1 CA3016588A CA3016588A CA3016588A1 CA 3016588 A1 CA3016588 A1 CA 3016588A1 CA 3016588 A CA3016588 A CA 3016588A CA 3016588 A CA3016588 A CA 3016588A CA 3016588 A1 CA3016588 A1 CA 3016588A1
Authority
CA
Canada
Prior art keywords
compound
subject
dose
zika virus
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3016588A
Other languages
English (en)
French (fr)
Inventor
Yarlagadda S. Babu
Pravin L. Kotian
Shanta Bantia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocryst Pharmaceuticals Inc
Original Assignee
Biocryst Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharmaceuticals Inc filed Critical Biocryst Pharmaceuticals Inc
Publication of CA3016588A1 publication Critical patent/CA3016588A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3016588A 2016-03-06 2017-03-06 Methods and compositions for treatment of zika virus infection Pending CA3016588A1 (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201662304317P 2016-03-06 2016-03-06
US62/304,317 2016-03-06
US201662324180P 2016-04-18 2016-04-18
US62/324,180 2016-04-18
US201662368111P 2016-07-28 2016-07-28
US62/368,111 2016-07-28
US201662370697P 2016-08-03 2016-08-03
US62/370,697 2016-08-03
US201662411867P 2016-10-24 2016-10-24
US62/411,867 2016-10-24
US201662414466P 2016-10-28 2016-10-28
US62/414,466 2016-10-28
US201762462852P 2017-02-23 2017-02-23
US62/462,852 2017-02-23
PCT/US2017/020961 WO2017155886A1 (en) 2016-03-06 2017-03-06 Methods and compositions for treatment of zika virus infection

Publications (1)

Publication Number Publication Date
CA3016588A1 true CA3016588A1 (en) 2017-09-14

Family

ID=59789791

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3016588A Pending CA3016588A1 (en) 2016-03-06 2017-03-06 Methods and compositions for treatment of zika virus infection

Country Status (9)

Country Link
US (3) US10512649B2 (https=)
EP (1) EP3426659A4 (https=)
JP (1) JP7046015B2 (https=)
AU (1) AU2017229105B2 (https=)
CA (1) CA3016588A1 (https=)
MA (1) MA43812A (https=)
MX (1) MX381542B (https=)
TW (1) TWI767903B (https=)
WO (1) WO2017155886A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020171080A1 (ja) * 2019-02-18 2020-08-27 株式会社栄養・病理学研究所 ブタにおけるｔ細胞の活性化度を評価する方法、ブタにおけるｔ細胞活性化を評価する剤、ブタｔ細胞活性化剤をスクリーニングする方法、ブタの病原体感染を検査する方法、及びハイブリドーマ

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US6228741B1 (en) 1998-01-13 2001-05-08 Texas Instruments Incorporated Method for trench isolation of semiconductor devices
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US7560434B2 (en) 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
NZ575365A (en) 2006-09-07 2012-02-24 Ind Res Ltd Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases
CA2663618A1 (en) 2006-09-11 2008-06-05 Southern Research Institute Azole nucleosides and use as inhibitors of rna and dna viral polymerases
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
PL2898885T3 (pl) 2010-10-15 2018-04-30 Biocryst Pharmaceuticals, Inc. Pochodne pirolopirymidynowe do zastosowania w leczeniu zakażeń wirusowych

Also Published As

Publication number Publication date
AU2017229105A1 (en) 2018-10-11
MX381542B (es) 2025-03-04
EP3426659A1 (en) 2019-01-16
US20210186976A1 (en) 2021-06-24
JP7046015B2 (ja) 2022-04-01
US10512649B2 (en) 2019-12-24
US20190083496A1 (en) 2019-03-21
WO2017155886A1 (en) 2017-09-14
AU2017229105B2 (en) 2021-08-12
US10933066B2 (en) 2021-03-02
TWI767903B (zh) 2022-06-21
EP3426659A4 (en) 2019-12-25
JP2019507195A (ja) 2019-03-14
US11975003B2 (en) 2024-05-07
MX2018010707A (es) 2019-03-28
US20200085830A1 (en) 2020-03-19
TW201731515A (zh) 2017-09-16
MA43812A (fr) 2018-11-28

Similar Documents

Publication Publication Date Title
JP5902698B2 (ja) ポリメラーゼの阻害のための方法および組成物
US20240269125A1 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
EP3854398B1 (en) Favipiravir for use in the treatment of coronavirus infection
KR101706624B1 (ko) 고병원성 감염성 질환의 예방 및 치료제
CN101743008A (zh) 用于治疗或预防登革热感染的抗病毒药
US20240261313A1 (en) Kit for preventing or treating filovirus and flavivirus diseases
RU2518314C2 (ru) Способ и средство активации irf-3 для лечения и профилактики заболеваний, вызываемых (+) phk-содержащими вирусами
US11975003B2 (en) Methods and compositions for treatment of Zika virus infection
CA2945825C (en) Inhibition of flaviviruses or chikungunya viruses using retinoic acid analogues
US20210353564A1 (en) Treatments for zika virus infection
AU2020382911A1 (en) Treatment and prevention of Dengue disease
CN104203228A (zh) 具有抗黄病毒的抗病毒活性的组合物
US12472197B2 (en) Methods, compositions, and dosing regimens for treatment of SARS-CoV-2 infections
Wutzler et al. Neuraminidase inhibitors in the treatment of influenza A and B–overview and case reports
CN114980885A (zh) 治疗hiv-1感染的方法
Chen et al. Tolvaptan, an FDA-approved drug, inhibits Zika virus infection both in vitro and in vivo.
WO2016089904A1 (en) Trans-clomiphene and its analogues as agents for treating or preventing filovirus diseases

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220307

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240905

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241216

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241216

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250116

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250506

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250506

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250506

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260302

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260302